Discovery of N-benzyl-2-((4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-(1,2,4)tri azolo(4,3-a)(1,5)benzodiazepin-6-yl)-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity.

导出原文传递

翻译打印收藏纠错

作者： Elliott RL ^[1] ; Cameron KO ; Chin JE ; Bartlett JA ; Beretta EE ; Chen Y ; Jardine Pda S ; Dubins JS ; Gillaspy ML ; Hargrove DM ; Kalgutkar AS ; LaFlamme JA ; Lame ME ; Martin KA ; Maurer TS ; Nardone NA ; Oliver RM ; Scott DO ; Sun D ; Swick AG ; Trebino CE ; Zhang Y

作者单位： Department of Cardiovascular, Metabolic, and Endocrine Diseases, Pfizer Global Research and Development, Groton, CT 06340, United States. ^[1]

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Bioorganic and Medicinal Chemistry Letters

2010年20卷22期

6797-6801页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Discovery of N-benzyl-2-((4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-(1,2,4)tri azolo(4,3-a)(1,5)benzodiazepin-6-yl)-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity.

Bioorganic and Medicinal Chemistry Letters

相似文献

Bioorganic and Medicinal Chemistry Letters

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Discovery of N-benzyl-2-((4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-(1,2,4)tri azolo(4,3-a)(1,5)benzodiazepin-6-yl)-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity.

Bioorganic and Medicinal Chemistry Letters

相似文献

Bioorganic and Medicinal Chemistry Letters

相关期刊

检索历史清除